查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995380

醫療相關感染疾病診斷市場：依檢測方法、病原體類型、檢體類型和最終用戶分類－2026-2032年全球市場預測

Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，醫療保健相關感染疾病診斷市場價值將達到 276.6 億美元，到 2026 年將成長至 298.2 億美元，到 2032 年將達到 497.7 億美元，複合年成長率為 8.75%。

主要市場統計數據
基準年 2025 276.6億美元
預計年份：2026年 298.2億美元
預測年份 2032 497.7億美元
複合年成長率 (%) 8.75%

為了抑制醫療相關感染疾病並提高病患安全，我們將概述在推廣下一代診斷技術方面面臨的緊迫的臨床、營運和政策挑戰。

醫療相關感染疾病對臨床醫生、實驗室技術人員和醫療系統而言始終是持續且不斷變化的挑戰。快速且準確的診斷是及時進行病患管理、合理使用抗生素和實施感染預防計畫的關鍵。隨著臨床路徑的日益整合和住院容量壓力的增加，診斷效能和工作流程的兼容性正成為醫療服務中日益重要的因素。

本研究檢驗了正在重塑整個醫療保健環境中的診斷工作流程、檢查室實踐和感染預防策略的變革性技術、監管和行為變化。

技術進步、監管環境的變化以及不斷湧現的臨床需求正在從根本上改變我們的診斷方式。分子診斷已從專業參考檢查室轉移到以患者為中心的醫療機構，從而能夠早期檢測病原體並快速制定治療策略。同時，免疫檢測平台也在不斷發展，自動化程度和連接性不斷提高，減少了人工操作，並在高通量環境下提高了結果的可重複性。

本研究分析了 2025 年美國關稅措施對供應鏈、價格趨勢、製造地決策和臨床採購行為的多方面影響。

關稅措施和貿易政策的變化會對整個診斷供應鏈產生連鎖反應，影響零件、耗材和組裝設備。 2025年，關稅體系的變化影響了試劑生產商和設備組裝的採購決策，促使一些機構實現供應商多元化並重新評估其庫存策略。對於檢查室管理人員和採購團隊而言，這些變化使得他們在保持檢測能力不間斷的同時，更加重視成本控制。

我們提供清晰的細分見解，將檢測方法、病原體特異性診斷、終端用戶檢測能力和檢體類型考慮因素與臨床效用和營運規劃聯繫起來。

詳細的市場區隔分析能夠提供切實可行的洞察，幫助我們了解價值創造的來源以及可能出現營運摩擦的環節。從檢測方法來看，市場可細分為免疫檢測、微生物學、分子診斷學三大類。免疫檢測包括化學化學冷光免疫檢測、酵素連結免疫吸附試驗 (ELISA) 和側向流動免疫分析，每種方法在處理能力、靈敏度和易用性方面各有專注。微生物學工作流程包括培養、顯微鏡檢查和藥敏試驗，其中培養可進一步細分為需氧培養和厭氧培養，這會影響檢查室佈局和培養通訊協定。分子橫向流動化驗包括等溫擴增、聚合酶鍊式反應 (PCR) 和定序方法，每種方法都有其獨特的基礎設施、負責人配置和資料解讀要求。

本報告分析了美洲、歐洲、中東和非洲以及亞太地區的區域趨勢，並指出了測試能力、部署模式和戰略市場進入考量的優勢。

區域趨勢對診斷技術的應用、監管協調和供應鏈發展有顯著影響。在美洲，成熟的檢查室基礎設施和完善的報銷機制催生了對快速、高通量解決方案和患者現場檢測的需求。該地區的相關人員通常優先考慮整合性、擴充性和供應商支援。相較之下，歐洲、中東和非洲（EMEA）的情況則較為複雜，監管差異、資源限制和不同的公共衛生優先事項導致了不同的應用模式。在許多市場，集中式參考檢測和滿足緊急需求的快速就地檢驗在局部並存。

我們分析主要企業及其競爭行為，以揭示影響診斷生態系統的產品系列、夥伴關係策略、創新管道和商業化方法。

企業行為和競爭定位對於決定醫療保健領域診斷能力的演變至關重要。主要企業正專注於採用組合式策略，平衡高通量檢查室系統、即時檢測平台和接近專利保護的平台，從而兼顧集中式檢測的經濟效益和分散式臨床需求。策略夥伴關係和分銷協議正在拓展地域覆蓋範圍，並支援在地化服務交付；而創新研發管線則體現了多實驗室能力、自動化和數位化連接等優先事項。

產業領導者提供切實可行的建議，以最佳化診斷系統部署、增強供應彈性，並使臨床工作流程與感染控制要求保持一致。

針對行業領導者的實用建議必須將策略洞察轉化為採購、檢查室營運和臨床管治方面的可操作步驟。首先，在評估新平台時，應優先考慮互通性和連接性，確保檢測結果與電子健康記錄、決策支援工具和監測系統無縫整合。這有助於減輕臨床醫生的認知負擔，並支持藥物管理計劃。其次，供應鏈風險評估應納入採購流程，評估替代試劑來源、前置作業時間差異以及供應商緊急時應對計畫，以避免在供應緊張時期出現服務中斷。

為了支持可靠的研究結果，我們描述了一種嚴謹的混合方法調查方法，該方法結合了對關鍵相關人員的訪談、對檢查室工作流程的觀察以及對二手證據的整合。

本分析採用混合研究方法，整合了來自一手和二手調查的數據，以得出可操作的見解。主要定性資料是透過對實驗室管理人員、感染疾病醫生、採購負責人和監管專家進行結構化訪談收集的，旨在了解實際操作情況、未解決的需求以及實施障礙。除訪談外，對不同環境下的檢查室工作流程進行直接觀察，有助於了解分析前階段的差異性、能力限制和整合挑戰。

將關鍵見解整合為連貫的策略建議，供醫療保健領導者、檢查室管理者和政策制定者參考。

這份總結性的綜合分析將研究結果提煉為針對醫療保健領導者、檢查室管理者和政策制定者的策略建議。診斷技術只有在能夠及時提供臨床決策所需的有效信息，並且檢查室工作流程能夠持續產出高品質、及時的結果時，才能發揮最大效用。技術創新，特別是分子診斷和自動化免疫檢測領域的創新，為轉變診斷模式提供了契機，但成功實施需要互通性、充足的人力資源和穩健的供應鏈。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按檢測方法分類的醫療相關感染疾病診斷市場

  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
    • 橫向流動化驗
  • 微生物學
    • 文化
      • 需氧培養
      • 厭氧培養
    • 顯微鏡檢查
    • 敏感性測試
  • 分子診斷
    • 等溫擴增
    • PCR
    • 定序

第9章：按病原體分類的醫療保健相關感染疾病診斷市場

  • 細菌
    • 困難梭狀芽孢桿菌
    • 大腸桿菌
    • 銅綠假單胞菌
    • 金黃色葡萄球菌
  • 真菌
    • 麴菌屬
    • 念珠菌屬
    • 新型隱球菌
  • 寄生蟲
    • 瘧疾原蟲
    • 弓形蟲
  • 病毒性的
    • 新冠病毒
    • 流感病毒
    • 諾羅病毒
    • 呼吸道融合細胞病毒

第10章：醫療相關感染疾病診斷市場－檢體類型

  • 血
    • 血清
    • 全血
  • 腦脊髓液
  • 呼吸系統
    • 支氣管肺泡灌洗液
    • 鼻咽拭子
    • 痰
  • 尿
    • 透過導尿管收集尿液
    • 中段尿
  • 傷口拭子
    • 深層組織檢體
    • 表面拭子

第11章：醫療保健相關感染疾病診斷市場：以最終用戶分類

  • 診斷檢查室
    • 獨立檢測實驗室
    • 參考檢測實驗室
  • 醫院
    • 臨床病理檢查室
    • 微生物檢查室
  • 照護端
    • 診所
    • 急診室
    • 長期照護機構

第12章：醫療保健相關感染疾病診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：醫療保健相關感染疾病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：醫療保健相關感染疾病診斷市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國醫療保健相關感染疾病診斷市場

第16章：中國醫療相關感染疾病診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • QIAGEN NV
  • Roche Diagnostics International AG
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-8760467AA424

The Healthcare-associated Infectious Disease Diagnostics Market was valued at USD 27.66 billion in 2025 and is projected to grow to USD 29.82 billion in 2026, with a CAGR of 8.75%, reaching USD 49.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 27.66 billion
Estimated Year [2026] USD 29.82 billion
Forecast Year [2032] USD 49.77 billion
CAGR (%) 8.75%

Framing the urgent clinical, operational, and policy imperatives driving next-generation diagnostic adoption to curb healthcare-associated infections and improve patient safety outcomes

Healthcare-associated infectious diseases represent a persistent and evolving challenge for clinicians, laboratory professionals, and health systems alike. Rapid and accurate diagnostics are core to timely patient management, antimicrobial stewardship, and infection prevention programs. As clinical pathways become more integrated and pressure on inpatient capacity intensifies, diagnostic performance and workflow fit are increasingly decisive factors in care delivery.

This introduction frames the diagnostic landscape through three interlocking lenses: clinical utility, operational feasibility, and policy alignment. Clinicians require actionable results that inform immediate treatment decisions. Laboratory managers must balance throughput, turnaround time, and cost while maintaining rigorous quality controls. Policy makers and infection control leaders need data that supports programmatic interventions and aligns with reimbursement and regulatory imperatives.

Consequently, the diagnostics ecosystem is no longer judged by analytic sensitivity alone; it is evaluated by its ability to integrate into electronic medical records, to support antimicrobial stewardship objectives, and to withstand supply chain disruption. This synthesis sets the stage for deeper analysis of technological shifts, regulatory currents, commercial responses, and pragmatic recommendations that follow in subsequent sections.

Examining the transformative technological, regulatory, and behavioral shifts reshaping diagnostic workflows, laboratory practices, and infection prevention strategies across care settings

The diagnostic landscape is undergoing a profound transformation driven by converging technological advances, shifting regulatory expectations, and newly elevated clinical demands. Molecular methods have moved from specialized reference labs into near-patient settings, enabling earlier detection of pathogens and faster therapeutic alignment. At the same time, immunoassay platforms are evolving to offer greater automation and connectivity, reducing manual steps and enhancing reproducibility across high-throughput environments.

Regulatory frameworks and quality expectations have evolved to prioritize clinical validation and real-world performance, which influences how vendors design trials and how laboratories implement new assays. Behavioral shifts among clinicians-driven by heightened awareness of antimicrobial resistance and infection prevention targets-have increased demand for diagnostics that deliver timely, actionable intelligence rather than isolated analytic results.

Operationally, automation and digital integration are reshaping laboratory workflows, creating opportunities to reassign skilled staff to higher-value tasks while standardizing processes to improve reliability. These dynamics collectively point to a landscape in which diagnostics are evaluated not only on accuracy but on how they accelerate care, reduce inappropriate antimicrobial use, and enhance system resilience.

Analyzing the multifaceted implications of United States tariff actions in 2025 on supply chains, pricing dynamics, manufacturing location decisions, and clinical procurement behaviors

Tariff actions and trade policy changes have the potential to reverberate through diagnostic supply chains, affecting components, consumables, and assembled instruments. In 2025, shifts in tariff regimes influenced sourcing decisions for reagent manufacturers and instrument assemblers, prompting some organizations to reassess supplier diversification and inventory strategies. For laboratory managers and procurement teams, these developments brought renewed attention to cost containment while maintaining uninterrupted testing capacity.

Manufacturers responded through a range of mitigation strategies, including near-shoring certain production stages, optimizing bill-of-materials to reduce exposed components, and negotiating long-term supplier contracts to stabilize input pricing. Meanwhile, clinical stakeholders emphasized the importance of validated alternatives and cross-validated workflows to ensure clinical continuity when preferred test kits are constrained.

The broader implication is that policy shifts can accelerate structural change across the diagnostics ecosystem. In response, health systems and laboratory networks are increasingly incorporating supply-chain risk assessments into technology adoption decisions, embedding contingency plans into procurement contracts, and advocating for clarity in trade policy to reduce operational uncertainty.

Delivering incisive segmentation insights that connect test methodologies, pathogen-specific diagnostics, end user capacities, and sample type considerations to clinical utility and operational planning

A granular view of segmentation offers practical insight into where value is created and where operational friction can arise. By test method, the landscape divides among immunoassays, microbiology, and molecular diagnostics. Immunoassays encompass chemiluminescent immunoassays, ELISA, and lateral flow assays, each offering different balances of throughput, sensitivity, and ease of use. Microbiology workflows include culture, microscopy, and sensitivity testing, with culture further differentiated into aerobic and anaerobic techniques that influence laboratory layout and incubation protocols. Molecular diagnostics feature isothermal amplification, PCR, and sequencing approaches; each method carries distinct infrastructure, personnel competency, and data-interpretation requirements.

When considering pathogen type, diagnostic strategies differ for bacterial, fungal, parasitic, and viral agents. Bacterial testing frequently targets organisms such as Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, where rapid identification and susceptibility insights directly affect antimicrobial therapy. Fungal diagnostics address Aspergillus species, Candida species, and Cryptococcus neoformans, which often require specialized assays and clinical correlation. Parasitic testing, including malaria parasites and Toxoplasma gondii, tends to be concentrated in specific clinical contexts, while viral testing for agents such as coronaviruses, influenza viruses, norovirus, and respiratory syncytial virus spans both routine surveillance and acute care decision-making.

End user characteristics shape adoption and implementation pathways. Diagnostic laboratories, including both independent and reference labs, prioritize scale, accreditation, and inter-laboratory comparability, whereas hospitals, through clinical pathology and microbiology laboratories, emphasize integration with clinical teams and rapid inpatient workflows. Point-of-care contexts such as clinics, emergency departments, and long-term care facilities demand compact platforms, simplified workflows, and rapid turnaround, which in turn influence assay format choices and validation strategies.

Sample type considerations-blood (serum and whole blood), cerebrospinal fluid, respiratory specimens (bronchoalveolar lavage, nasopharyngeal swabs, sputum), urine (catheterized and midstream), and wound swabs (deep tissue and surface swabs)-further dictate pre-analytical controls, transport logistics, and analytic sensitivity thresholds. The interplay among test method, pathogen target, end user, and sample type creates a multidimensional decision matrix that stakeholders must navigate when prioritizing investments, selecting platforms, and designing implementation pathways.

Interpreting regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific to reveal capacity strengths, adoption patterns, and strategic market entry considerations

Regional dynamics materially affect diagnostic adoption, regulatory alignment, and supply chain architecture. In the Americas, maturity in laboratory infrastructure and established reimbursement pathways create a demand environment for rapid, high-throughput solutions alongside near-patient testing; stakeholders here often prioritize integration, scalability, and vendor support models. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory variation, resource constraints, and diverse public health priorities drive differential adoption patterns; in many markets, centralized reference testing coexists with pockets of rapid point-of-care rollouts in response to acute needs.

Asia-Pacific is characterized by a wide range of capabilities, from highly advanced metropolitan laboratory networks to regions with limited access to complex platforms. This diversity shapes manufacturer strategies around modular systems, language-appropriate software, and local partnerships to ensure adoption and serviceability. Across all regions, procurement behaviors, public health imperatives, and infrastructure investments influence how diagnostics are prioritized, with connectivity and data interoperability increasingly seen as cross-cutting enablers for regional surveillance and clinical decision-making.

Consequently, strategic entry and scale-up decisions must reconcile regional regulatory pathways, logistics constraints, and clinical practice norms with the technical attributes of targeted diagnostic solutions. Stakeholders that align product offerings with regional operational realities are better positioned to achieve sustained clinical uptake and system impact.

Profiling leading companies and competitive behaviors to highlight product portfolios, partnership strategies, innovation pipelines, and commercialization approaches that influence diagnostic ecosystems

Company behavior and competitive positioning are central determinants of how diagnostic capabilities evolve across care settings. Leading manufacturers emphasize a portfolio approach that balances high-throughput laboratory systems with point-of-care and near-patient platforms, thereby addressing both centralized testing economies and decentralized clinical demands. Strategic partnerships and distribution agreements expand geographic reach and provide local serviceability, while innovation pipelines reflect priorities such as multiplexing capability, automation, and digital connectivity.

Product differentiation increasingly hinges on end-to-end value propositions: not only the analytic performance of assays but also instrumentation uptime, consumable logistics, cloud-enabled data interpretation, and training programs for laboratory staff. Firms that invest in robust post-market evidence generation and that collaborate with health systems on implementation pilots secure credibility with clinical users and procurement teams. Additionally, a competitive emphasis on sustainability-through reduced single-use plastics and optimized reagent packaging-affects procurement preferences and long-term relationship management.

As commercial players adapt to evolving policy environments and supply-chain pressures, their strategic choices around manufacturing footprints, platform modularity, and service ecosystems will determine how readily health systems can deploy and scale diagnostic solutions in pursuit of improved infection management.

Presenting actionable, high-impact recommendations for industry leaders to optimize diagnostic deployment, strengthen supply resilience, and align clinical workflows with infection control imperatives

Actionable recommendations for industry leaders must translate strategic insight into implementable steps across procurement, laboratory operations, and clinical governance. First, prioritize interoperability and connectivity when evaluating new platforms so results can seamlessly integrate with electronic medical records, decision support tools, and surveillance systems; this reduces cognitive load on clinicians and supports stewardship programs. Second, embed supply-chain risk assessments into procurement cycles by evaluating alternate reagent sources, lead-time variability, and vendor contingency plans to avoid service disruptions during periods of constrained supply.

Third, standardize validation and verification protocols across networked laboratories to enable rapid scale-up of new assays while maintaining comparability and quality assurance. Fourth, invest in workforce development to ensure laboratory staff are trained in molecular and digital workflows; reallocating staff from repetitive tasks to higher-value data interpretation improves system resilience. Fifth, adopt a phased implementation approach for novel diagnostics that includes clinical pilots, multidisciplinary reviews, and feedback loops that capture real-world performance and workflow impact.

Finally, align commercial contracting with outcomes-oriented metrics where feasible, incorporating uptime guarantees, bundled service offerings, and joint post-market evidence generation to de-risk adoption for health system customers. Taken together, these steps will accelerate responsible deployment of diagnostic innovations that materially reduce infection-related harms.

Explaining a rigorous mixed-methods research methodology combining primary stakeholder interviews, laboratory workflow observations, and secondary evidence synthesis to underpin credible findings

This analysis is grounded in a mixed-methods research approach that synthesizes primary and secondary evidence to generate actionable insight. Primary qualitative data were gathered through structured interviews with laboratory directors, infectious disease clinicians, procurement officers, and regulatory experts to capture operational realities, unmet needs, and adoption barriers. These interviews were complemented by direct observations of laboratory workflows in diverse settings to understand pre-analytical variability, throughput constraints, and integration challenges.

Secondary evidence was curated from peer-reviewed literature, regulatory guidance documents, and manufacturer technical specifications to validate assay attributes and to triangulate performance claims. Where possible, comparative assessments leveraged published analytic performance metrics and documented implementation case studies to inform practical considerations around training, maintenance, and connectivity.

Analytic rigor was maintained through standardized interview guides, cross-validation of thematic coding, and transparent documentation of assumptions used in interpretive synthesis. The resulting methodology privileges operational relevance and clinical applicability, ensuring that conclusions are actionable for decision-makers responsible for procurement, laboratory operations, and infection control policy.

Concluding synthesis that distills key insights into coherent strategic takeaways aimed at healthcare leaders, laboratory managers, and policy makers for decisive action

This concluding synthesis distills the analysis into strategic takeaways for healthcare leaders, laboratory managers, and policy makers. Diagnostics are most impactful when they deliver actionable intelligence within clinical decision windows and when laboratory workflows are designed to sustain high-quality, timely outputs. Technological innovation-particularly in molecular methods and automated immunoassays-creates opportunities to shift diagnostic paradigms, but successful adoption depends on interoperability, workforce readiness, and supply-chain robustness.

Policy and procurement levers can accelerate deployment when they incentivize real-world evidence generation, support workforce development, and incorporate contingency planning into contracts. Regional dynamics and end-user characteristics matter: solutions that are technically excellent but misaligned with local workflow, regulatory realities, or sample logistics will struggle to achieve sustained uptake. Therefore, a holistic approach that aligns clinical needs, laboratory capabilities, and commercial models is essential for delivering measurable improvements in infection prevention and patient outcomes.

Taken together, the findings underscore that integrated planning, cross-functional collaboration, and adaptive procurement strategies are central to translating diagnostic innovation into clinical and operational impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method

  • 8.1. Immunoassays
    • 8.1.1. Chemiluminescent Immunoassay
    • 8.1.2. ELISA
    • 8.1.3. Lateral Flow Assays
  • 8.2. Microbiology
    • 8.2.1. Culture
      • 8.2.1.1. Aerobic Culture
      • 8.2.1.2. Anaerobic Culture
    • 8.2.2. Microscopy
    • 8.2.3. Sensitivity Testing
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. PCR
    • 8.3.3. Sequencing

9. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type

  • 9.1. Bacterial
    • 9.1.1. Clostridium Difficile
    • 9.1.2. Escherichia Coli
    • 9.1.3. Pseudomonas Aeruginosa
    • 9.1.4. Staphylococcus Aureus
  • 9.2. Fungal
    • 9.2.1. Aspergillus Species
    • 9.2.2. Candida Species
    • 9.2.3. Cryptococcus Neoformans
  • 9.3. Parasitic
    • 9.3.1. Malaria Parasites
    • 9.3.2. Toxoplasma Gondii
  • 9.4. Viral
    • 9.4.1. Coronavirus
    • 9.4.2. Influenza Virus
    • 9.4.3. Norovirus
    • 9.4.4. Respiratory Syncytial Virus

10. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Serum
    • 10.1.2. Whole Blood
  • 10.2. Cerebrospinal Fluid
  • 10.3. Respiratory
    • 10.3.1. Bronchoalveolar Lavage
    • 10.3.2. Nasopharyngeal Swabs
    • 10.3.3. Sputum
  • 10.4. Urine
    • 10.4.1. Catheterized Urine
    • 10.4.2. Midstream Urine
  • 10.5. Wound Swabs
    • 10.5.1. Deep Tissue Samples
    • 10.5.2. Surface Swabs

11. Healthcare-associated Infectious Disease Diagnostics Market, by End User

  • 11.1. Diagnostic Laboratories
    • 11.1.1. Independent Laboratories
    • 11.1.2. Reference Laboratories
  • 11.2. Hospitals
    • 11.2.1. Clinical Pathology Laboratories
    • 11.2.2. Microbiology Laboratories
  • 11.3. Point Of Care
    • 11.3.1. Clinics
    • 11.3.2. Emergency Departments
    • 11.3.3. Long Term Care Facilities

12. Healthcare-associated Infectious Disease Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Healthcare-associated Infectious Disease Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Healthcare-associated Infectious Disease Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Healthcare-associated Infectious Disease Diagnostics Market

16. China Healthcare-associated Infectious Disease Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. bioMerieux SA
  • 17.9. Danaher Corporation
  • 17.10. DiaSorin S.p.A.
  • 17.11. QIAGEN N.V.
  • 17.12. Roche Diagnostics International AG
  • 17.13. Siemens Healthineers AG
  • 17.14. Sysmex Corporation
  • 17.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032